Ocugen CEO to Present at J.P. Morgan 2026 Healthcare Conference

Core Insights - Ocugen, Inc. is set to present at the 44th Annual J.P. Morgan Healthcare Conference from January 12-15, 2026, highlighting its advancements in gene therapies for blindness diseases [1][2] - The company aims to file three Biologics License Applications (BLAs) in the next two years, including a rolling BLA for OCU400 targeting retinitis pigmentosa this year [2] Company Overview - Ocugen, Inc. is a biotechnology leader focused on gene therapies for blindness diseases, utilizing a modifier gene therapy platform that addresses complex diseases caused by imbalances in multiple gene networks [4] - The company is developing therapies for inherited retinal diseases and other blindness conditions affecting millions globally, including retinitis pigmentosa, Stargardt disease, and geographic atrophy [4] Presentation Details - Dr. Shankar Musunuri, Chairman and CEO, will present on January 15, 2026, from 9:45 to 10:25 a.m. PST at the Colonial Room, Mezzanine [3] - A live video webcast of the presentation will be available on Ocugen's investor site, with a replay accessible for a limited time [3]